Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 4/20 | 0.57 |
| ▸ | VIPR2 | P41587 | 2/20 | 0.50 |
| ▸ | NPY5R | Q15761 | 3/20 | 0.49 |
| ▸ | NPY1R | P25929 | 2/20 | 0.49 |
| ▸ | NPY4R | P50391 | 2/20 | 0.49 |
| ▸ | GLP1R | P43220 | 1/20 | 0.49 |
| ▸ | GCGR | P47871 | 1/20 | 0.49 |
| ▸ | GIPR | P48546 | 1/20 | 0.49 |
| ▸ | VIPR1 | P32241 | 2/20 | 0.48 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.48 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.48 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.48 |
| ▸ | TFPI | P10646 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16507926 | 0.88 | NPY4R (0.53) | RXFP1NPY5RNPY1RNPY4RGLP1R | |
| SCHEMBL16508129 | 0.87 | NPY4R (0.52) | RXFP1NPY5RNPY1RNPY4RGLP1R | |
| SCHEMBL16507762 | 0.85 | TFPI (0.56) | RXFP1GLP1RGCGRGIPRTFPI | |
| SCHEMBL16507937 | 0.85 | RXFP1 (0.55) | RXFP1VIPR2NPY5RNPY1RNPY4R | |
| SCHEMBL16507855 | 0.85 | RXFP1 (0.55) | RXFP1VIPR2NPY5RNPY1RNPY4R | |
| SCHEMBL13363672 | 0.84 | RXFP1 (0.54) | RXFP1NPY5RNPY1RNPY4RGLP1R | |
| SCHEMBL16507959 | 0.83 | RXFP1 (0.59) | RXFP1GLP1RGCGRGIPRTFPI | |
| SCHEMBL10168810 | 0.82 | NPY5R (0.50) | RXFP1NPY5RNPY1RNPY4RGLP1R | |
| SCHEMBL16508090 | 0.82 | NPY4R (0.58) | RXFP1NPY5RNPY1RNPY4RGLP1R | |
| SCHEMBL31130725 | 0.82 | NPY4R (0.53) | RXFP1NPY5RNPY1RNPY4RGLP1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110294738-A1 | PTHR1 RECEPTOR COMPOUNDS | ANTHOR THERAPEUTICS, INC. | 2011-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110294738-A1 | PTHR1 RECEPTOR COMPOUNDS | PTH1R, MC1R, CASR | RXFP1 568/4885VIPR2 843/4885NPY5R 1478/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.